Advantages of Off-the-Shelf CAR NK Therapy in B-Cell Malignancies

Video

Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.

Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.

There are several CAR NK products in development at Fate Therapeutics; some products are in clinical trials and some are in preclinical development. The NK cell has 3 modalities: CD19 to target B-cell malignancies, CD16 to be combined with monoclonal antibodies that target B-cell malignancies, and recombinant fusion of interleukin (IL)-15 and IL-15RF, which overcomes the lack of persistence of NK cells, says Valamehr. That trimodality targeted structure, combined with product’s off-the-shelf use, could provide patients with cost-effective therapy in a timely manner.

Research with this platform suggests that an adoptive cell therapy can be converted into a pharmaceutical drug product, says Valamehr. It also suggests that NK cells can be engineered to be more effective. Additionally, the product can house multiple antitumor modalities on 1 cell to overcome the heterogeneity or evolution of cancer growth, concludes Valamehr.

Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
© 2025 MJH Life Sciences

All rights reserved.